Latest Posters

This poster explores how a robust CRISPR-based screening platform enables the identification of novel regulators of the Treg phenotype to support drug discovery.

This poster highlights the importance of exploring the spatial organization of the entire transcriptome in cancer tissues and presents a powerful platform for unraveling the complexities of the TME.

This poster explores how 6-base whole-genome sequencing of cfDNA boosts the sensitivity of liquid biopsy tests for early cancer detection.

This poster outlines a scalable workflow combining tangential flow filtration and size exclusion chromatography to effectively isolate and purify exosomes, removing contaminants including media, serum and host cell proteins, DNA and serum components.

This poster highlights how this technology can provide accurate detection of genetic variants and variant-associated methylation in colorectal cancer samples.

This poster presents a solution that can offer results in less than 1.5 days, producing sequencing-ready libraries from total nucleic acid samples.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtype. However, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumor is a small minority.

Traditionally, there has been a compromise between performance and sustainability.

Researchers looking to answer complex biological questions often require increased statistical power, larger studies and deeper sequencing methods.